Moro-Sibilot D, Pluquet E, Zalcman G, Bréchot J-M, Souquet P-J, Debieuvre D, Morin F, Morère J-F
PMAC pneumologie, CHU A. Michallon, BP217X, 38043 Grenoble cedex, France.
Rev Mal Respir. 2007 Oct;24(8 Pt 2):6S120-4.
Patients with poor performance status (PS) and advanced lung cancer have been underrepresented in clinical trials. As a consequence, the management of these patients in clinical practice is often empirical. Recent data indicate that patients with advanced non-small cell lung cancer (NSCLC) and a PS of 2 tend to benefit from first line chemotherapy with respect to symptom improvement and perhaps overall survival. Whether single-agent or combination chemotherapy is preferable remains debatable. In previously treated patients with NSCLC, EGFR tyrosine kinase inhibitors produced a substantial rate of clinical benefit and led to an improvement in survival compared with placebo in studies that included a significant percentage of patients with poor PS.
身体状况较差（PS）的晚期肺癌患者在临床试验中的代表性不足。因此，在临床实践中对这些患者的治疗往往是经验性的。最近的数据表明，晚期非小细胞肺癌（NSCLC）且PS为2的患者在症状改善以及可能的总生存期方面倾向于从一线化疗中获益。单药化疗还是联合化疗更优仍存在争议。在先前接受过治疗的NSCLC患者中，在纳入了相当比例PS较差患者的研究中，与安慰剂相比，表皮生长因子受体（EGFR）酪氨酸激酶抑制剂产生了相当高的临床获益率并延长了生存期。
